叶定伟 教授

叶定伟教授,复旦大学附属肿瘤医院副院长,泌尿外科学科带头人,泌尿肿瘤MDT首席专家,上海市泌尿肿瘤研究所所长,复旦大学前列腺肿瘤研究所所长,中国抗癌协会泌尿男生殖系肿瘤专委会主任委员,中国临床肿瘤学会(CSCO)前列腺癌专委会主任委员,CSCO尿路上皮癌专委会副主任委员,CSCO肾癌专委会副主任委员和CSCO免疫治疗专委会副主任委员,中国肿瘤医院泌尿肿瘤协作组(UCOG)主任委员,中国抗癌协会常务理事,CSCO常务理事,NCCN肾癌诊治指南中国版编写组副组长,NCCN前列腺癌、肾癌和膀胱癌亚洲诊治共识专家委员会委员,晚期前列腺癌亚太共识专家委员会委员,上海市医师协会泌尿外科医师分会副会长,前上海市抗癌协会理事长,国科金二审专家,亚太前列腺癌学会(APPS)执行委员及2019年会大会主席,亚太冷冻外科学会副会长,《亚洲男科学杂志》(AJA)副主编,《前列腺癌和前列腺疾病杂志》(PCPD)和《英国国际泌尿学杂志》(BJUI)编委。
擅长泌尿男生殖系统肿瘤的手术和综合治疗,每年主刀根治手术近千台。主持国家级、省部级科研基金50余项。以第一作者或通信作者发表论文543篇(SCI 296篇),包括Nature genetics,JCO,EU,CCR,CR等。主编主译专著9本,发明和实用新型专利19项。牵头国际国内多中心临床实验和研究50余项。以第一完成人获上海市科技进步一等奖2项、教育部科技成果一等奖二等奖各1项、上海市医学科技奖一等奖1项、中华医学科技奖二等奖和中国抗癌协会科技奖二等奖各1项,以第三完成人获国家科技进步一等奖1项。获国家卫健委有突出贡献中青年专家,吴阶平泌尿外科医学奖,药明康德生命化学研究奖,上海市领军人才,上海市医学领军人才,上海市优秀学科带头人,全国卫生计生系统先进工作者称号,享受国务院特殊政府津贴。

Prof. Dingwei Ye, Vice President of the Fudan University Shanghai Cancer Center, Director of the Multi-disciplinary Team for GU cancer, Director of Shanghai Genitourinary Cancer Institute, Director of Fudan University Prostate Cancer Institute, President of Chinese Anti-Cancer Association-Genitourinary Oncology Committee, President of Chinese Society of Clinical Oncology (CSCO) Prostate Cancer Committee, Vice president of CSCO Urothelial Cancer Committee, Vice president of CSCO Kidney Cancer Committee and CSCO Immunotherapy Committee, Standing Committee Member of Chinese Anti-Cancer Association, Standing Committee Member of CSCO, committee member of NCCN Asia consensus of prostate cancer, renal cancer and bladder cancer, committee member of APCCC Asia consensus,decisive reviewer of National Scientific Foundation of China, executive member and 2019 Annual Congress Chairman of Asian Pacific Prostate Society, Vice President of Asia Cry-surgery Society.  Associate Editor of “Asian Journal of Andrology”, editorial board member of “Prostate Cancer and Prostatic Diseases” and “British Journal of Urology International”.
Prof. Ye had 543 papers published in peer review journals as the first author or corresponding author, edited 9 monographs, obtained 19 patents. He has led over 50 international or national multicenter clinical trials and studies for GU cancer as leading PI.